{"id":"W2133117185","doi":"10.1093/infdis/jiu051","title":"Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study","year":2014,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":329,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"Janssen Pharmaceuticals; Gilead Sciences; ViiV Healthcare; GlaxoSmithKline; National Institute of Allergy and Infectious Diseases; Pfizer; Bristol-Myers Squibb; Abbott Laboratories","keywords":"Elvitegravir; Dolutegravir; Raltegravir; Medicine; Discontinuation; Regimen; Tolerability; Integrase inhibitor; Adverse effect; Viral load; Internal medicine; Population; Phases of clinical research; Pharmacology; Clinical trial; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004928862,0.0002595513,0.0005807072,0.0002234497,0.0001867646,0.00002794956,0.000195796,0.00003840797,0.00001353719],"category_scores_gemma":[0.000358997,0.0001058152,0.000119176,0.0005005312,0.0001948243,0.0001402376,0.00005940153,0.0002530203,0.000001636002],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001173474,"about_ca_system_score_gemma":0.0002094224,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001078072,"about_ca_topic_score_gemma":0.0001461595,"domain_scores_codex":[0.9978314,0.0003473342,0.0007510048,0.0001774292,0.0006435242,0.0002493206],"domain_scores_gemma":[0.9982811,0.0002882453,0.000669868,0.0003644714,0.0002315587,0.0001648133],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02621467,0.008799764,0.9538406,0.00004006295,0.0003249153,0.00005697914,0.005644571,0.00002315366,0.0004867227,0.00001681549,0.0004457198,0.004106083],"study_design_scores_gemma":[0.06212386,0.01097605,0.9211605,0.000596695,0.00100355,0.00005527506,0.002704159,0.00004043368,0.0006260991,0.00008691,0.0004122486,0.0002142582],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9984007,0.0001569112,0.00002748257,0.0002674839,0.0001259365,0.0007829117,0.00002968988,0.00001500155,0.0001939157],"genre_scores_gemma":[0.9992589,0.0000584591,0.00003596192,0.0000830374,0.00005648756,0.00001266619,0.000007773615,0.00002161076,0.0004651266],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03590919,"threshold_uncertainty_score":0.431502,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008909296242199214,"score_gpt":0.2590626394812267,"score_spread":0.2501533432390275,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}